Clinical

Dataset Information

0

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer


ABSTRACT: The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatures of response.

DISEASE(S): K-ras Wild Type Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms,Colorectal Cancer Metastatic

PROVIDER: 2098880 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| PRJNA92971 | ENA
2013-11-18 | E-GEOD-52471 | biostudies-arrayexpress
2013-11-18 | GSE52471 | GEO
| PRJNA1047182 | ENA
2021-05-06 | PXD021673 | Pride
2026-03-09 | GSE297035 | GEO
2010-04-08 | E-GEOD-14006 | biostudies-arrayexpress
2009-07-17 | E-GEOD-13579 | biostudies-arrayexpress
2007-06-25 | E-GEOD-4888 | biostudies-arrayexpress